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Development and implementation of a dynamic heterogeneous proton equivalent
anthropomorphic thorax phantom for the assessment of scanned proton beam
therapy
By: James Leroy Neihart, B.S.
Chair of Advisory Committee: David Followill, Ph.D
Proton therapy has been gaining ground recently in radiation oncology. To date, the most
successful utilization of proton therapy is in head and neck cases as well as prostate cases.
These tumor locations do not suffer from the resulting difficulties of treatment delivery as a
result of respiratory motion. Lung tumors require either breath hold or motion tracking, neither
of which have been assessed with an end-to-end phantom for proton treatments. Currently, the
RPC does not have a dynamic thoracic phantom for proton therapy procedure assessment.
Additionally, such a phantom could be an excellent means of assessing quality assurance of the
procedures of proton therapy centers wishing to participate in clinical trials. An eventual goal
of this phantom is to have a means of evaluating and auditing institutions for the ability to start
clinical trials utilizing proton therapy procedures for lung cancers. Therefore, the hypothesis of
this study is that a dynamic anthropomorphic thoracic phantom can be created to evaluate endto-end proton therapy treatment procedures for lung cancer to assure agreement between the
measured and calculated dose within 5% / 5 mm with a reproducibility of 2%. Multiple
materials were assessed for thoracic heterogeneity equivalency. The phantom was designed
from the materials found to be in greatest agreement. The phantom was treated in an end-to-end
treatment four times, which included simulation, treatment planning and treatment delivery.
Each treatment plan was delivered three times to assess reproducibility. The dose measured
within the phantom was compared to that of the treatment plan. The hypothesis was fully
supported for three of the treatment plans, but failed the reproducibility requirement for the
most aggressive treatment plan.
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1
1.1

Introduction and Background
Statement of Problem

1.1.1 General Problem
Until recently proton therapy has been limited to research institutions or physics
departments because of the immense size and cost of proton therapy facilities. Each
system was created as a one-of-a-kind. Currently, proton therapy is in a state of rapid
expansion and implementation at large medical institutions as well as smaller standalone facilities. Proton accelerators have recently been designed to fit within a single
linear accelerator vault [1], which allows radiation oncology departments to add proton
therapy to their practice in a retrofitted treatment vault. Because proton accelerators
come in many sizes, beam line configurations, and particle acceleration methods
radiation quality assurance (QA) measurements must be made before all proton beams
can be assumed to deliver comparable doses to clinical targets. Since the number of
proton therapy sites and clinical trials that employ proton therapy are increasing, an
effort to establish dose delivery consistency must be in place to assure that multiinstitution clinical studies are valid. Worldwide there are 37 proton centers currently
operational [2].

An additional twenty-four institutions worldwide are also in the

process of constructing or developing proton facilities, many of which are single gantry
systems [3].
The Radiological Physics Center (RPC) was established in 1968 to assure the
NCI and Cooperative Study Groups that institutions participating in clinical trials
1

delivered clinically comparable and consistent radiation doses [4]. One of the most
efficient means of assuring a participating institution’s beam delivery is to mail a
phantom fitted with dosimeters and have them irradiate it following a treatment plan in
an end-to-end QA test. Such a QA system saves time for the RPC and creates a
standard irradiation condition for various participating institutions.

The RPC has

experience with numerous phantom and dosimeter configurations optimized for linear
accelerator, brachytherapy and proton treatment applications [4] [5] [6].
1.1.2 Specific Problem
Current thoracic phantoms used by the RPC are designed specifically for use in
photon beams.

However, materials and plastics used in these phantoms do not

correspond to tissue equivalent materials when placed in a proton beam instead of a
photon beam as the phantoms were originally designed. The goal of this research is to
develop and commission a phantom which will serve to assess the ability of a proton
facility to deliver a planned dose to a target within a lung heterogeneity influenced by
respiratory motion without having to manually override material properties in the
treatment planning system.

The phantom will be composed of tissue simulating

materials, which in the thorax includes materials that have vastly different proton
stopping power ratios. The phantom is intended to be easily mailed to institutions
intending to participate in current or future clinical trials pertaining to proton therapy of
lung cancer.
1.1.3 Importance of Topic
While the theoretical advantages of proton therapy are numerous, and are
discussed in detail in sections 1.5.1 and 1.5.10, proton therapy treatments still require
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clinical trials to prove efficacy, although some in the field debate this [7]. Clinical trials
are an essential aspect of scientific advancement in the medical community. Proton
therapy clinical trials are currently needed to determine the efficacy of treating with
protons as opposed to the current standard of care photon treatments. Current and
proposed proton trials are made more difficult by the fact that each proton therapy
center worldwide is designed and built differently. With a large variation in the beam
delivery and treatment parameters available at different proton centers, the need for an
end-to-end quality assurance tool becomes imperative to assure consistency of patient
data from different centers. The mission of the RPC is especially important in the case
of proton therapy, where there is less uniformity of beam delivery systems than in linear
accelerator photon delivery. Inconsistencies and incomparable delivered doses reduce
the efficacy of clinical trials and can compromise validity of conclusions, thus they
must be minimized systematically as much as possible. The use of a well-designed
anthropomorphic QA phantom helps to ensure that the treatment delivered across
participating institutions is comparable.
Lung and bronchus cancer has the second highest estimated age-adjusted
incidence rates for men and women in 2012 within the United States, but is the leading
cancer in estimated age-adjusted mortality rates for the same cohort [8]. Although the
mortality rate for men has been decreasing since the mid-1990s, lung cancer remains the
highest cancer in mortality rate for the US population.

Local tumor control has

commonly been to blame for the high mortality associated with lung cancer. Proton
therapy exhibits the potential for higher dose escalation than achievable by IMRT or
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other photon beam techniques, which may increase local control in patients without
compromising dose to surrounding critical structures.
1.2

Hypothesis
A dynamic heterogeneous anthropomorphic thorax phantom can be designed and

built to evaluate the end-to-end proton therapy treatment procedures for lung cancer to
assure agreement between the measured and calculated dose within ±5%/5 mm with a
reproducibility of ±2%.
Specific Aims:
1. Determine tissue equivalent materials for protons for soft tissue, lung and bone.
2. Design and build a lung anthropomorphic QA phantom for proton therapy using
the identified tissue equivalent materials.
3. Image the dynamic phantom with 4D CT and develop a clinically applicable
treatment plan for scattered and spot scanned proton beams.
4. Irradiate the phantom according to the treatment plans with point and planar
dosimeters to generate measured dose distribution.
5. Compare the measured and planned dose distributions and determine accuracy
and precision.
1.3

Research Approach

Methodology:
1. Tissue equivalency will be determined by measured proton stopping powers and
HUs corresponding to anatomical data.
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2. The phantom will be designed with lung tissue, soft tissues, and bone simulating
materials in an anthropomorphic and clinically relevant size and geometry.
3. The phantom will be imaged with a 4DCT scanner to utilize the time varying
capabilities of the imaging modality.

The image will be used to develop

treatment plans (scattered and scanned beams) using Eclipse proton planning
system and will be generated based on typical clinical constraints and practices
used by PTC-H dosimetry for lung cancer.
4. The phantom will accommodate TLD capsules and radiochromic film for
dosimetry measurement.

The phantom will be irradiated according to the

treatment plan at least three separate times for each plan.
5. The measured dose distributions and point doses will be compared to the
calculated planned distributions and point doses using a gamma analysis will be
used to determine agreement and reproducibility.
1.4

Limitations

1.4.1 Limitations of the Phantom
The design of the phantom must make assumptions as well as neglect certain
aspects of a human thorax during irradiation. Fundamentally in design, the phantom
cannot simulate all types of tumor motion. Shirato et. al have shown that various 3dimensional trajectories are possible within the lungs based on location within the
thorax as well as other factors such as attachment to the ribs or diaphragm [9]. The
dosimetry insert is limited in design to a single tumor location as well as a restriction on
rotation because the sensitivity to setup error of the orthogonal films [10]. Additionally,
the motion insert as well as the static portion of the phantom restrict the possibility of
5

deformable anatomy during the breathing cycle. For more information on deformable
inserts or higher degrees of motion including rotation, the reader is referred to studies
[11] and [12] respectively.
The simulated breathing pattern is also subject to limitations that differ from
clinical possibilities. The breathing patterns used must assume amplitude as well as
periodic function. Others have shown that a simple sinusoidal breathing pattern may
not accurately simulate interplay effects [13]. Summarized by the AAPM Report No.
91, the amplitude of lung tumor motion can vary widely, thus any single choice in
amplitude will result in limited clinical applicability. However, the amplitude of tumor
motion for a single patient during 4D simulation as well as treatment may in fact be
accurately simulated by a single choice in amplitude for tumor motion [14].
1.4.2 Limitations of the Proton Beam Delivery System
The beam delivery system used for this study was the synchrotron accelerator at
the PTC-H at MD Anderson Cancer Center. Synchrotron based spot scanning has
limitations due to the time it takes for the beam to change energy, which have been
studied by others, [15] and is discussed in section 1.5.3.2.

Specifically, if the

respiratory cycle is close to the energy change time, the interplay effect may result in
unacceptable dose deliveries [13].
The spot size at the PTC-H at MD Anderson Cancer Center also presents a
limitation on the dose conformity delivered to the relatively small tumor volume. The
spot size of the scanning beam at the Proton Therapy Center at MD Anderson Cancer
Center is approximately 5 mm at 250 MeV and 10 mm at 70 MeV with the use of an
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energy absorber [16]. Thus, smaller tumor diameters may receive insufficient delivered
dose due to the large spot size.
1.5

Literature Review

1.5.1 Protons in Therapy
Proton beams for therapy have a number of advantages over photons. These
advantages arise because of the physical differences of the proton as compared to the
photon and the manner in which the proton deposits energy as it passes through matter.
The most obvious advantage of protons in radiation therapy is the high
ionization density near the end of the range of the proton [17]. This property of protons
as they slow down in a medium allows the maximum energy deposition to be chosen as
opposed to the predetermined depth of maximum dose as in photon therapy treatments
[18]. Figure 1.1 demonstrates the dose deposition as a function of depth in water of a
monoenergetic proton beam.
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Relative Dose

Proton Bragg Peak

Depth in Water

Figure 1.1: Depth dose curve of a "pristine" proton beam
Because the proton is a charged particle, it exhibits a finite range that is a
function of its kinetic energy. This property is advantageous because healthy tissue
distal to the target can be spared with minimal doses.
Clinically, a monoenergetic proton beam is not used because solid tumors have
non-zero depth. The use of either range modulators, ridge filters or the superposition of
many monoenergetic beams produces a spread out Bragg peak (SOBP), shown in
Figure 1.2. The plateau of the SOBP can be further extended by the addition of lower
energy pristine Bragg peaks; doing so will also increase the relative dose at the entrance
of the tissue.
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Relative Dose

Spread out Bragg Peak formation

Depth in Water (cm)

Figure 1.2: Formation of an SOBP from multiple pristine Bragg peaks
Proton therapy results in a lower integral dose than traditional photon treatments
[19]. This property is a strong rationale for the utilization of proton therapy in the
treatment of pediatric malignancies such as medulloblastoma where the effect of a low
integral dose is easily noticeable when comparing treatment plans. A lower integral
dose is associated with a lower rate of second malignancies as a result of the treatment.
In the specific case of lung cancer, the lower integral dose from proton therapy reduces
the lung, heart and spinal cord dose volume histograms (DVHs), which may be doselimiting to the target in photon therapy techniques.
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The lateral penumbra of a proton beam is generally much sharper than that of a
photon beam with the exception of high energy photon beams at depths greater than
approximately 22 cm in water [20]. The lateral penumbra of a proton beam increases as
the protons travel through air, the patient, or other materials in the beam path.
Maintaining a small penumbra is clinically desirable because it creates greater dose
falloff outside the tumor volume.

Without accurate end-to-end positional

reproducibility, a beam with a small penumbra has the potential to underdose the target
or deliver high dose to normal tissue. A treatment plan utilizing high dose gradients
near target borders or critical organs may yield exceptional DVH characteristics, but
upon treatment delivery, may yield undesirable dose delivery.
1.5.2 Radiobiology of Proton Therapy
Heavy charged particles demonstrate radiobiologic advantages over X-rays.
These advantages include improved relative biological effectiveness (RBE) and oxygen
enhancement ratio (OER). In a highly conformal therapy, an improved RBE is one that
is increased above unity. Conversely, an improved OER is one that approaches unity.
The equations for RBE and OER are shown below in Equation 1 and Equation 2
respectively, and in both equations the doses are for the same biological effect.

(

)

Equation 1
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Equation 2

Current clinical proton doses are modified by a RBE of 1.1. This means that
protons yield the same biological endpoint as photons at a physical dose 10% lower
than photons. The clinical use of this constant RBE value was based on in vitro and in
vivo studies of murine tumors [21]. The proton therapy research community generally
recognizes that proton RBE is a function of linear energy transfer (LET), and dose, but
both relationships are still under investigation [22]. While the constant value of RBE
may not be correct, it provides a good average and is easily implemented in a clinical
setting.

Uncertainty in the biological effects of proton therapy translates to an

uncertainty in appropriate tumor doses as well as critical structure limitations. In the
future, proton therapy treatment planning systems may be able to optimize biological
effective dose distributions.
In regions of hypoxia, the OER is an important metric of treatment
effectiveness. As the LET of a particle increases at the end of its pathlength, the OER
decreases [23]. At an LET of approximately 200 keV/µm, the OER of a cell line
approaches unity, meaning the increased cellular damage of a high LET particle is equal
in effectiveness to the decrease in cellular damage due to the hypoxic environment [24].
However, this enhancement is smaller in clinical proton beams where the maximum
LET in the distal falloff region of the Bragg peak is on the order of 10 keV/µm [22].
Additionally to tumor hypoxia, normal tissue distal to the tumor may be enhanced by
the OER because of the high LET distal to the target.
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1.5.3 Proton Accelerators
1.5.3.1 Cyclotron
Cyclotron accelerators produce monoenergetic protons and are also called
isochronous cyclotrons.

The energy for proton therapy is typically 250 MeV to

accommodate the highest practical energy needed for treatment procedures, but this
may vary between proton center, proton machines or treatment applications. Desired
clinical energies lower than the maximum accelerated value are achieved by the use of
energy degraders [25].
The most significant advantage of proton cyclotron accelerators is that they
produce a constant beam current [25]. This allows the beam intensity to be adjusted
rapidly. In the case of a moving lung tumor, future advances may allow for real-time
tracking where the proton beam energy would rapidly modulate to accommodate tumor
motion. However, with the use of energy degraders, the beam divergence may increase
without additional downstream focusing magnets. A disadvantage of cyclotrons is that
there is a potential for significant beam loss within the accelerator, which results in
machine hardware becoming radioactive [25].

This is also true of any additional

hardware put in the beam path.
1.5.3.2 Synchrotron
Synchrotrons have the ability to accelerate protons to a range of different
energies. The PTC-H, for example, has the ability to accelerate protons to 94 discrete
energies from 72.5 – 250 MeV without the use of an energy degrader [16]. Energy
modulation however, is not rapid because the beam is extracted in pulses, or “spills”.
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The common energy change rates for synchrotrons are between 0.5 and 5 seconds [25].
Faster energy selection can be accomplished by the use of a range modulator wheel in
the beam line, however; range modulator wheels are only used for passive scattered
beam delivery and they produce a specific SOBP for use with a single accelerated
proton energy.
1.5.4 Proton Beam Delivery Methods
1.5.4.1 Passive Scattered Beams
The most straightforward method of delivering a charged particle beam is by the
passive scattered method. Passive scatter beam modifying components include range
modulators, apertures and range compensators. A monoenergetic proton beam, with a
pristine Bragg peak has too sharp of a peak to cover clinically relevant treatment
volumes [18]. Therefore, a means of changing the energy of the proton beam is needed
to cover the treatment volume in the depth dimension. In passive scattering, this is done
by using of a range modulator.
Neutron dose in the passively scattered proton beam is higher than that of the
spot scanned proton beam. Neutron dose generated from within the patient by the
protons undergoing nuclear interactions is unavoidable regardless of the delivery
method. Neutron dose from the nuclear interactions within the scattering system in the
beam gantry, however, is minimized in the spot scanned system. In passive scattered
beams, this external neutron dose can be minimized by increasing the proton utilization
efficiency [26]. Practically, this can be achieved by selecting the smallest achievable
beam size for a given aperture.
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As its name implies, passive scattering ultimately is a passive beam delivery
method, thus for a dynamic system such as a lung tumor located in healthy aerated lung
tissue, the passive scatter technique is inherently suboptimal without further advanced
techniques.
1.5.4.2 Spot Scanned Beams
Due to the electromagnetic charge of the proton, a thin beam of protons can be
steered by the use of magnets [26]. Two common names for this delivery method are
spot scanning and pencil beam scanning. Scanned beams are dynamically modified
before entering the patient, therefore they do not require any patient specific hardware
such as collimators or compensators [18].
As mentioned in section 1.5.4.1, the secondary neutron dose is lower in a
scanned system than a passively delivered beam.

The secondary neutron dose is

unwanted and not accounted for in treatment planning or tolerance limits of critical
structures.
A major advantage spot scanned proton beams have over passively delivered
beams is the ability to generate intensity modulated proton therapy (IMPT) treatment
plans. Intensity modulation has shown to be a successful technical progression in
photon therapy, and has given clinical staff the ability to inverse plan a treatment. In
the same way, intensity modulation for proton therapy seems to be a logical step from
forward planned treatments. Each individual scanned pencil beam has the ability to be
optimized to create a homogeneous dose distribution within the target volume over a
sufficient number of fields [26].

14

1.5.5 Range Uncertainties in Proton Therapy
One of the attractive properties of proton therapy is the rapid energy deposition
at the end of the range of the proton beam. Additionally, distal to the high dose
gradient, there is very little dose deposited. The possibility for tissue sparing distal to
the target volume is a key advantage of proton therapy over conventional photon
therapy. However, this dose distribution of the proton also has its disadvantages.
Errors resulting in range uncertainties are exacerbated in proton therapy where
the energy deposition of the proton is highly concentrated at the end of its range. This
phenomenon makes proton beam delivery much more sensitive to tissue
inhomogeneities than photon beam dose deliveries [1]. This effect is shown in Figure
1.3. The photon beam is relatively unaffected by 1 mm of additional water equivalent
thickness (WET) of material, while the coverage of the SOBP is noticeably shifted,
however the maximum relative dose within the target is unchanged. An additional
difficulty in proton beam delivery is that when these tissue inhomogeneity range
uncertainties occur, the target can receive a severe under-dose, and surrounding healthy
tissue can receive unintended maximum dose levels.
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Effects of range uncertainty in photon and proton
beams
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Figure 1.3: Illustration of the effects of an additional millimeter of WET in an
SOBP and 6 MV beam
In the case of lung cancer, the tumor with density properties similar to water is
located within or adjacent to aerated low density lung tissue. This presents a different
dosimetric situation than tumors located in more uniform tissue such as the brain or
prostate. The stopping power of lung tissue is approximately three times lower than
that of soft tissue, thus the proton beam travels further in lung tissue. Uncertainty in the
range results in an exacerbated effect in lung tissue, as the high dose deposited by the
proton beam travels farther in lung tissue than in soft tissue distal to the target [26].
Additionally, the range adjustment step becomes approximately three times larger
spatially between layers of dose that can be delivered in lung tissue compared to soft
16

tissue for spot scanned beam delivery. The density variation along a path from the skin
to a lung tumor presents an added complexity to proton therapy delivery.
Range and dose uncertainties are also introduced by the calibration of
Hounsfield units (HU) to relative stopping power (RLSP). Because the interactions of
photons and protons differ in matter, a calibration curve is necessary to plan a proton
therapy treatment on a CT image set.

Using stoichiometric and empirical data, a

calibration curves has been generated from animal tissues to show a bilinear calibration
curve relating HU to RLSP [27]. Experimental verification has shown that the total
uncertainty in the soft tissue portion of the calibration curve is ±1.1% while the high
HU portion of the calibration curve associated with bone is ±1.8% [28].
1.5.6 Intrafractional Motion of Lung Tumors
In addition to the differences in densities ranging from bone to lung tissue that
the proton beam may traverse, delivering a charged particle beam to tumors located in
the lung is also complicated by respiratory motion. Tumor motion is typically primarily
in the superioinferior direction [26]. Typical techniques that are used for both photon
and proton therapy respiratory motion mitigation are discussed in section 1.5.8.
Intrafractional motion results in potential errors in radiation dose delivery when
the motion is severe and motion mitigation techniques are either not used or underutilized. The consequences of both interfractional and intrafractional motion include
unintentional target misses, reduced target coverage and elevated normal tissue dose.
Due to the plan uncertainty, the intrafractional tumor motion is accounted for by 4DCT
plans for patients [29].
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Real time tumor motion has been tracked by diagnostic fluoroscopy with the use
of gold markers, which were inserted into the tumor [9] [30].

Of the studies

summarized in the AAPM Report No. 91, the range of motion in the SI direction alone
was 0 – 34 mm [14]. These studies and others have provided lung tumor motion data
for many patients but have no common trajectory. Research has also shown that lung
tumor motion is independent of tumor size, location within the lung, or extent of
pulmonary function [31]. Therefore, modern radiotherapy treatment of lung cancer
requires a 4DCT scan to assess the magnitude and direction of each patient’s motion
because there is not an a priori motion pattern.
1.5.7 Imaging Acquisitions for Thoracic Tumors in Proton Therapy
Because respiratory motion is the most severe intrafractional motion in the
human body, time resolved imaging techniques can serve to better define the ITV of the
lung tumor. Others have shown that 3-dimensional imaging is inadequate for proton
treatment planning of lung tumors [32].

4DCT scans effectively result in a 3-

dimensional imaging set for each of the binned respiratory phases. Treatment planning
in proton therapy utilizes the HU recorded by the CT scanner to calculate the relative
stopping power of each pixel.
The binning of respiratory phases is done by the use of a motion monitoring
device. Examples of clinical devices used are spirometers, which measure airflow,
strain gauges, which measure abdominal circumference, and fiducials tracked by rigid
cameras, which measure one dimensional movement of the chest [33]. These devices
provide reproducible measurements which act as a surrogate for tumor motion.
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Many clinics and researchers use a commercial fiducial and camera system
called Real-time Position Management™ (RPM) (Varian Medical Systems, Palo Alto,
CA). This device uses a rigidly fixed CCD camera located at the inferior end of the
imaging or treatment couch and a box containing two or six reflective fiducial markers.
The rigid camera also contains an infrared light. The emitted infrared light reflects off
of the fiducial reflectors and is detected by the CCD camera. An image of the rigid
infrared light and camera system is shown in Figure 1.4 below.

Figure 1.4: The RPM infrared camera system used in free breathing and breath
hold simulations and treatments
The acquisition of both the CT slice and the respiratory phase is used to
construct a phase dependent image set. At MD Anderson Cancer Center, the respiratory
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cycle is divided into 10 phases for 4DCT acquisitions. The information gained from a
4DCT acquisition includes range and direction of tumor motion in 3-dimensions,
motion of critical organs, and a baseline breathing pattern of the patient to identify
irregular breathing amplitudes during treatment.

Although 4DCT generates phase

dependent imaging, motion still exists in between the phase bins. This uncertainty
however is much smaller than that of a single 3D imaging acquisition and has been
measured to blur an object by up to 8% of its length due to interphase motion and the
interplay effect [34]. The 4DCT image set is used for treatment planning and is also
used to better facilitate additional motion mitigation techniques mentioned in the
following section.
1.5.8 Motion Mitigation Techniques
Currently motion mitigation techniques include rescanning, beam gating, and
beam tracking [35].

These motion management techniques are listed in order of

conformality as well as sophistication in delivery. Many of the motion mitigation
techniques for proton therapy can benefit from the efforts made on conventional photon
therapy respiratory motion mitigation.
Rescanning is simply taking advantage of the law of averages. If the treatment
includes many fractions, an area of over dose in one fraction may be an area of under
dose in another fraction. With regards to the interplay effect, fractionation was found to
reduce dose deviations up to 33% from a single fraction beam delivery [36]. This
principal can also be further applied when each fraction includes many irradiations of
each spot separated in time to achieve the desired dose in that fraction. Currently
different rescanning techniques are being investigated, such as volumetric [36], and
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patient specific optimization [37].

However, until more advanced techniques are

validated clinically, rescanning does not offer optimization and should only be used
when no other motion mitigation technique can be used effectively.
Beam gating is a motion mitigation technique that limits beam on time to phases
of the respiratory cycle where the tumor is located in the beam path. As the tumor
moves out of the beam path, the beam turns off until the tumor reenters the beam path.
The target, however, still moves during each phase. Therefore the motion mitigation
achieved by beam gating is only by reducing the motion within the beam-on time, not
eliminating the effect of target motion [35]. Additionally, gating in this manner also
makes the assumption that the tumor motion during simulation is identical to that during
the time of treatment.
Respiratory motion can be reduced by breathing techniques. Shallow breathing,
for example, results in a reduced tumor amplitude during the breathing cycle. Even
more so, breath-hold techniques can potentially freeze the respiratory motion while the
beam is on.

The most important aspect of these breathing techniques is the

reproducibility of the breathing pattern.

Experimental measurements using a

spirometer-based monitoring system yielded an average reproducibility in the tumor
position of approximately 3 mm in patients [38]. Beam gating under breath hold
conditions provides a powerful motion mitigation technique used in both photon and
proton therapy.
The most complex of the motion mitigation techniques is beam tracking. Beam
tracking is the continuous repositioning of the beam path and energy based on image
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guided tumor position or other tumor motion surrogates. Beam tracking can only be
used in spot scanning beam delivery, because of the active beam steering and range
modulation required. This technique requires patient monitoring as well as a proton
accelerator capable of changing beam energy rapidly. Beam tracking has the potential
to be the most conformal motion mitigation technique, but at the cost of high technical
complexity [35].
1.5.9 Thoracic Phantoms in Proton Therapy
Dynamic and static phantoms have been used in photon therapy to good success.
Commercial systems include motion inserts which can accommodate imaging, and
multiple types of dosimeters. Tissue equivalent materials in photon beams are used to
simulate tissue heterogeneities.
The materials which are tissue equivalent in photon beams are not necessarily
tissue equivalent in proton beams. Because of this, thoracic phantoms used in proton
beams should be made of materials that simulate tissue accurately within a proton beam
otherwise the materials must have their properties, such as HU or RLSP, manually
changed within the treatment planning software. The latter strategy has been used by
others because of the commercially available materials and phantoms. An example is a
PVC artificial skeleton used with a robotic arm to move a detector bank with 6dimensional motion [12]. This configuration is quite complex, however PVC does not
simulate tissue adequately enough to avoid manual override of the HU of the ribs. The
RPC measured a 12% underresponse of PVC RLSP with respect to the Eclipse
calculated RLSP.
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1.5.10 Current State of Proton Therapy in Lung Cancer
Currently, proton therapy is used to treat thoracic cancers at many institutions in
the United States. Of the institutions monitored by the RPC, each uses a unique
combination of motion management techniques, immobilization devices, lateral margins
and setup tolerances. The potential benefits of proton therapy over photon therapy for
thoracic tumors include: smaller beam penumbrae, finite range of protons, and dose
escalation due to normal tissue sparing [32].
The potential for dose escalation is an important feature of the use of proton
therapy in thoracic cancers. Local control in lung cancer patients with total doses up to
65 Gy under standard fractionation in photon radiation therapy was found to be less
than 20% [39].

A clinical trial of photon therapy dose escalation for NSCLC

demonstrated that a total dose of approximately 84 Gy resulted in a TCP of 50% as
compared to a TCP of approximately 25% at 70 Gy [40]. The results of this study
showed a sigmoid-shaped dose response curve. However, the common limiting factor
to dose escalation in photon therapy is the unacceptable dose to normal tissue or critical
organs. Because protons stop with a finite range, many in the radiation oncology field
see a benefit from protons in achieving high dose in the tumor volume while also
maintaining tolerable doses to normal and critical tissue.
1.5.10.1 Critical Organ Threshold Doses
Critical structures in the thorax include the contralateral lung, heart and spinal cord.
The dose these critical structures receive during treatment depends on the tumor
location, motion and size. Spinal cord, total lung, and heart dose-volume constraints
used at MD Anderson Cancer Center for definitive radiation therapy in thoracic
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treatments are shown in Table 1.1 [39]. The spinal cord is a serial organ, meaning that
the maximum dose determines the likelihood of complication, which in the case of the
spinal cord, is paralysis.

Other organs in the thorax exhibit a parallel structure for

radiation damage. Patients irradiated above a high maximum dose over a small lung
volume or irradiated above a relatively low maximum dose over a large lung volume
have an increased risk of severe pneumonitis. Radiation-induced cardiac side-effects
have been of concern in the treatment of thoracic malignancies as well as breast
irradiations. The heart exhibits both limitations on maximum tolerable total volume
dose as well as a secondary dose-volume constraint shown below.
Organ

Dose

Volume

Spinal cord

50 Gy

-

Lung

20 Gy

<40%

Heart

40 Gy

<100%

50 Gy

<50%

Table 1.1:

Dose-volume constraints for three common critical structures in

thoracic radiotherapy treatments

2
2.1

Materials and Methods
Phantom Design

2.1.1 Phantom Design Considerations
Due to the high sensitivity of range uncertainties in proton therapy, the phantom
should be designed in such a way as to minimize unnecessary air gaps, material
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interfaces and materials of unacceptably different stopping powers than those of
anatomical equivalents.

In order to properly account for the clinically applicable

anatomical heterogeneities, the phantom should include heterogeneities in the beam
path such as bone and lung. The design should include a section of lung that is able to
move freely by an actuator with high reproducibility.
The dosimetry insert should be able to accommodate absolute point dose
dosimeters such as TLD. Additionally, the insert should be able to accommodate
radiochromic films to measure dose distributions within the phantom. The dosimetry
measurements provided by the films can be normalized by the absolute point dose from
the TLD, which corresponds to a designated point in the film plane [41].
A proton dosimetry insert previously designed by Blatnica was used in the
design of this phantom. The insert was designed to minimize the air gaps present in
previous photon dosimetry inserts which were not as sensitive to air gaps in comparing
the planned and measured dose distributions. The design considerations of the insert
included choosing proton-appropriate materials, maintaining proper film orientation,
and minimizing air gaps [6]. An image of the insert is shown in Figure 2.1.
The insert is composed of balsa wood and is covered by a thin high impact
polystyrene cylinder. Within the center of the insert is a high impact polystyrene
ellipsoid which is the clinical target and simulates the gross tumor volume.
The design should also include a heart structure which can accommodate film.
This addition of an avoidance structure with planar dosimetry allows for out of field or
distal dose measurements.
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Due to the dose distributions in proton therapy, a phantom with a single lung will
provide a sufficient simulation of a typical anatomical proton therapy case. Others have
shown that the contralateral lung V5, even with dose escalation, is lower in proton
therapy than IMRT plans at conventional doses [42]. Therefore, the ipsilateral lung is
the only lung necessary; the contralateral lung will receive negligible dose because the
low dose distribution distal to the target volume. Considering the low distal dose, the
spinal section was also omitted from the phantom design. Conventional proton therapy
beam angles for thoracic cases never enter through the contralateral lung. Due to the
limited treatment angles that the phantom accommodates, this decision is justifiable
without noticeable effect on the dose delivered to the target. Future studies with this
phantom may incorporate dosimeters at the location of the spinal cord simply by the
addition of a cord material capable of accommodating dosimeters.

The clinically

relevant toxicity for the spinal cord is a maximum dose of 50 Gy [42]. Under the
current design with a tumor located central within the left lung, it is unlikely that a
proton therapy institution would deliver a dose of 50 Gy to the spinal cord.
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Figure 2.1: The assembled dosimetry insert used within the phantom (left) and a
view of the target within the balsa wedges (right)
The initial intended motion of the tumor is approximately 2 cm in amplitude in
the superoinferior direction and 0.7 cm in amplitude in the anteroposterior direction, but
can be programmed to any clinically applicable amplitude. This motion simulates a
possible normal tumor motion pattern [9]. The phantom should be designed in such a
way that motion tracking surrogates such as a chest displacement or abdominal
circumference tracking systems can be used to facilitate gated treatment delivery.
The phantom incorporates five proton equivalent material types.

These

materials simulate lung, soft tissue, heart, tumor, and bone. The materials chosen have
relative stopping powers which are very close to those calculated by Eclipse Treatment
27

Planning System (TPS) at their respective Hounsfield units (HU). The design of the
phantom should be consistent with human anatomy as well as provide non-uniform
linear geometry to ensure that the beam delivery is non-trivial during simulated
treatments. Figure 2.2 below shows the relative stopping power and HU of the tissue
simulating materials used in the phantom compared to calculated values from the TPS.

Figure 2.2: Phantom material RLSP and HU over Eclipse calculated curve
2.1.2 Determination of Bone Equivalent Material
An adequate proton-equivalent bone material was needed to simulate ribs within
the phantom without having to contour them and manually adjust their HU for accurate
calculation of proton ranges by the TPS. In order to verify that a material is proton
equivalent to the TPS calculated stopping power based on the material’s HU, the
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relative stopping power must be measured. Equation 3 below is a modified version of a
relative stopping power equation for a test material in front of a water tank [43].
(

)

Equation 3

RLSP is the relative stopping power, R80,w is the distance in water to the distal
80% ionization depth, R80,m is the distance in water beyond the test material to the distal
80% ionization depth, tm is the thickness of the test material. The measurements for
relative stopping power were done using a Zebra Multi-Layer Ion Chamber (IBA,
Schwarzenbruck, Germany). All samples were irradiated with a 10 cm x 10 cm field
with a SOBP of 10 cm. Each range measurement was irradiated to 50 MU. An image
of the measurement setup is shown in Figure 2.3 below.

Figure 2.3: Relative stopping power measurement setup
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A total of nine materials were tested for bone equivalency using the setup
mentioned above. Six of the materials were plasters or clays, two were dense woods
and one was bone meal. Human ribs were considered as a natural option to incorporate
within the phantom, however, they were not used because human ribs are brittle once
dried and develop air pockets where the spongy bone was previously contained.
2.1.2.1 Error Analysis in RLSP and HU Measurements
In order to test for reproducibility, error analysis was needed to determine if a
difference in HU or RLSP was acceptable or unacceptable. The HU measurements
were done within Eclipse TPS and 10 HU values were taken from a line of pathlength
through the material. The standard deviation of the HU was reported in Figure 3.2 as
positive and negative horizontal error bars.
Each variable in Equation 3 above has uncertainty in its measurement. The
range accuracy of the distal 80% depth for water and the material is determined by the
accuracy of the depth scanning device. The Zebra has a range accuracy of ± 0.5 mm.
The thickness of the machined materials was determined to also have an accuracy of ±
0.5 mm. The propagated fractional error in the relative stopping power is shown in
Equation 4 below. This uncertainty analysis was used in the generation of figures in
section 3.2.1 and section 3.1.

√

√

(
(

)

Equation 4

)
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2.2

Breathing Motion of Dosimetry Insert

2.2.1 Insert Motion Method
The simulated motion of the tumor was carried out by both an electromechanical
cylinder and a lead screw based motor moving the dosimetry insert at an angle of 20º
through the phantom. This method may simulate clinical situations better than having
the phantom on an oscillating motion table because the ribs, heart, and soft tissue
surrounding the lungs do not translate during respiratory motion.

Others have

successfully demonstrated the use of motion tables [44]. Additionally, a combination of
motion table and electromechanical cylinder to simulate respiratory motion has also
been studied [11].
The electromechanical cylinder used was the Dyadic SCN6-020-100 (Dyadic
Systems Co., Ltd. Japan).

The cylinder is shown in Figure 2.4.

Following the

simulations, and two irradiations the Dyadic electromechanical cylinder lost
communication with the PC controller and was replaced with a Velmex BiSlide MN100050-E01-31 (Velmex Inc., Bloomfield, NY) shown in Figure 2.5.
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Figure 2.4: Electromechanical cylinder used to move the dosimetry insert

Figure 2.5:

Lead screw driven motor assembly used to replace the

electromechanical cylinder
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2.2.2 Insert Motion Types
The electromechanical cylinder and lead screw motor are limited to 1dimensional motion; however, 2-dimensional motion can be simulated with the insert at
an angle with respect to the treatment couch plane. As mentioned in section 2.1.1, the
initial intended motion is approximately 2 cm in amplitude along the SI direction and 7
mm along the AP direction. At an incline of 20º, the motion results in an amplitude of
approximately 2.13 cm along the motion insert travel direction. Clinically 2 cm motion
is large for many proton facilities therefore a reduced target motion of 1.5 cm in
amplitude was also generated for free breathing treatments.
2.2.3 Dosimetry Insert Motion Control
The electromechanical cylinder was controlled by software included with the
device (PC Tool Kit, Dyadic Systems Co. Ltd., Japan). The software allows for control
over many parameters of the electromechanical cylinder. The hardware allows for 256
bytes of information to be loaded to the cylinder, which is sufficient for multiple
simulated breathing types [11]. Additionally motion was controlled by VMX software,
which also allows for 256 bytes of information to be stored on the controller.
2.3

Dosimetry
The phantom was designed to accommodate both point and planar dosimetry as

mentioned in section 2.1.1 above. The combination of planar and point dosimetry has
been used by the RPC for many years to good success.

The dosimetry insert

accommodates two TLD capsules and five pieces of film to generate three planes.
Additionally, a single piece of film was utilized at the surface of the heart.
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2.3.1 Point Dosimetry
The point dosimeter used in the phantom was TLD. TLD provides an absolute
dose measurement at the location of the dosimeter. The RPC has extensive experience
with TLD usage and is capable of generating reliable readings [45].
TLDs are passive detectors that can store integrated dose until they are read out
with a heating cycle. The mechanism for storing and reading dose deposited is similar
to semiconductor detectors which exploit the presence of impurities that produce an
electron-hole trap between the valence and conduction band of the powder [46]. Once
the TLD is irradiated, it can be read out by heating the powder to release the electronhole pairs from the impurity traps, which releases thermoluminescent photons that are
counted by a photomultiplier tube system.

In order to use TLDs for an absolute

dosimeter, many parameters must be identified and calibrated. This process has been
studied by RPC to ensure reliable analysis of measurements.
The RPC uses a LiF based TLD called TLD-100 (Harshaw Chemical Company,
Solon, OH). It is doped with Mg and Ti ions as the trapping and luminescence centers.
This particular thermoluminescent material is sensitive to photons, thermal neutrons and
charged particles [47]. The lower threshold for reliable measurements is approximately
100 µGy [46]. The determination of delivered dose to a TLD is calculated by Equation
5, where M is the thermoluminescent signal per unit mass of powder,
sensitivity,

is the linearity correction factor,

is the system

is the energy correction factor, and

is the fading correction factor.
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(

)

Equation 5

The fading correction factor, KF is determined at the RPC by a double
exponential function shown in Equation 6. Where a, b, c, d and N are batch specific
coefficients and x is the number of days between irradiation and TLD reading. These
coefficients are determined through experimentation upon implementation of a new
batch of TLD powder by the RPC. The energy correction factor, KE is unity for proton
beams.

(

)

Equation 6

The linearity correction factor, KL is determined at the RPC by a linear function.
Equation 7 is used by the RPC for the batch specific linearity correction factor, where m
and b are batch specific coefficients.

These are also determined through

experimentation upon implementation of a new batch of TLD powder.

Equation 7

The determination of the system sensitivity requires the use of standards which
are irradiated to known doses using a 60Co machine. The system sensitivity is solved by
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taking the irradiated dose of the standard TLD divided by fading correction, linearity
correction and the average reading per milligram of the standard TLD powder.
The use of TLD-100 has been validated for proton beams by experimentation
and was demonstrated to have a standard deviation of less than ±4.0% [48]. This result
is consistent with the expected ±5.0% uncertainty typically associated with
thermoluminescent dosimetry.
TLD measures physical dose while the TPS calculates biological dose. The
TLD physical dose was multiplied by the RBE of 1.1 for protons to yield the Cobalt
centi-Gray Equivalent (CcGE).
2.3.1.1 TLD Calibration
By the method described above, the TLD calibration was performed starting
with the irradiation of standards. The standards were irradiated to 800 cGy by a

60

Co

machine, which was used because the dosimetry output on cobalt machines is very
stable. The characterization of the fading, linearity and energy correction coefficients
has been performed previously by the RPC for the batch of TLD used, batch B11.
Because the standards are of the same batch of TLD powder, their calibration was valid
to use on the TLD irradiated in the phantom.

The fading, linearity and energy

correction coefficients for this batch of TLD powder are tabulated in Table 2.1 and
Table 2.2.
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Coefficient Value
a

1.2815

b

0.00010885

c

0.06781

d

0.071908

N

1.3493

Table 2.1: TLD correction coefficients used in Equation 6 for fading for batch B11
Coefficient Value
m

-0.000335

b

1.100495

Table 2.2 TLD correction coefficients used in Equation 7 for linearity for batch
B11
2.3.2 Planar Dosimetry
The planar dosimetry used in the phantom was GAFChromic® EBT2 film
(International Specialty Products, Wayne, NJ) lot number: A03081203 with an
expiration date of March 2014. A diagram of this film is shown in Figure 2.6 [6]. The
use of orthogonal films through the target allows for the reconstruction of isodose
curves to compare with the original planned dose distribution. These measured 2D
planes can be compared to those in the original treatment plan to assess the accuracy of
delivery by means of the gamma index [49].
37

Figure 2.6: Crossection of EBT2 film
Another piece of film from the same batch as those in the tumor isocenter was
used as a means of measuring the heart dose at its surface. The heart is a critical
structure in thoracic cases because it may be unintentionally irradiated distal to the
target. The film at the heart surface provides dosimetry for the heart. From the planar
dose distribution at the surface of the heart, the maximum heart dose will be measured
and inferences on the DVH of the heart can be made. Because the heart film was
designed without a point dosimeter for normalization, the film was used as a qualitative
tool to visually assess irradiated dose distributions. Due to the low planned doses near
the heart structure, the utilization of a calibration curve for the film may result in large
uncertainties.
In addition to providing an accurate means for 2D dosimetry, the active layer of
EBT2 is approximately water equivalent in effective atomic number [10]. However,
effective atomic number of the active layer does not equate to water equivalence for
relative stopping power for the sheet of film. Therefore, in proton measurements, EBT2
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film has a relative stopping power approximately 8.0% higher than the Eclipse
calibration curve as measured by the RPC. At normal incidence to the beam, this
discrepancy only corresponds to a range uncertainty of less than 0.03 mm. With the
film parallel to the beam, this uncertainty may become unacceptably large. To avoid
this effect, others have tilted film at angle no less than 5o to the parallel beam axis [10].
GafChromic EBT films have been shown to under respond in the Bragg peak region of
proton beams [50] [51]. As the residual energy of a proton beam reduces below
approximately 15 MeV, the magnitude of under response can reach as high as 20% [50]
[51]. Because of this measured effect, measured doses in the distal region of the beams
are expected to be lower than the TPS calculated doses.
2.3.2.1 Film Calibration
In order to determine a dose from the optical density of a film, the film must
undergo a calibration to determine an empirical function for optical density vs. dose.
The calibration was performed at the PTC-H by PTC-H staff. Sections of a piece of
film were irradiated to physical doses ranging between 45 cGy to 636 cGy at a depth
located at the center of a 160 MeV passive scattered SOBP in a 10 cm x 10 cm field
under solid water. The optical density of each section of the calibration film was read
three times by a CCD Microdensitometer for Radiochromic Film Model CCD100
(Photoelectron Corporation, Lexington, MA) to provide an accurate average OD for
each dose level. As a result, the dose as a function of optical density was determined to
be of the form of a third order polynomial in Equation 8 fit to the curve illustrated in
Figure 2.7.
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D = -8.9981(OD)3 + 29.72(OD)2 - 3.1581(OD)

Equation 8

Film Calibration
7
6
y = -8.9981x3 + 29.72x2 - 3.1581x
R² = 0.9936
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Figure 2.7: Film calibration curve and equation of fit for EBT2 lot #A03081203 in
a clinical proton beam
2.4

Imaging Acquisitions
As mentioned in section 1.5.7, a 4DCT imaging acquisition is the preferred

imaging acquisition for a thoracic tumor for proton therapy planning. In addition to a
free breathing 4DCT, a breath hold CT was also taken of the phantom. Images for the
breath hold treatment and the 2.13 cm amplitude spot scanned treatment were acquired
by a Discovery ST PET/CT (General Electric HealthCare, Waukesha, WI). Images for
the 1.5 cm amplitude free breathing treatments were acquired by a LightSpeed RT 16
CT (General Electric HealthCare, Waukesha, WI).

Proton treatment planning was
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performed on the 4DCT image sets and is discussed in sections 2.5.1 and 2.5.2. An
image of the simulation setup is shown in Figure 2.8 below.

Figure 2.8: Phantom assembly setup for imaging acquisition
2.4.1 4DCT
The phantom was placed on the treatment couch and assembled.

Plastic

fiducials were placed at the location of the localization lasers used by the radiation
oncology department for patient localization on treatment machines. The motion insert
controlling device was set to repeat the free breathing motion profile indefinitely.
Two 4DCT acquisitions were taken of the phantom in a free breathing
simulation state which had 2.13 cm amplitude and 1.5 cm amplitude.

The scans

consisted of a scout scan and imaging acquisitions at each axial slice position for a
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duration of 7 seconds. The 7 second cine duration allows for 1 second added to the
approximate respiratory cycle of 6 seconds for the free breathing motion profile.
The 4DCT acquisitions consisted of 2880 images which were binned by
respiratory phase. The respiratory phases were acquired by the RPM system by placing
the reflective box on the adapter platform designed for the electromechanical cylinder.
Traditional binning generated some noticeable artifacts on the periphery of the phantom
thus a modification of the phasing bins was performed which allowed for the peaks of
inspiration and expiration to be better matched with their respective phase bins. The
modified binning generated a 4DCT data sets which had fewer visual artifacts. A
maximum intensity projection (MIP) and average CT set were generated for both the
traditionally binned and modified binned 4DCT data sets.
2.4.1.1 Maximum Intensity Projection
From the acquired 4DCT data set, a 3D MIP was generated. A MIP contains the
maximum voxel intensity from the ten phased image sets. The MIP is particularly
useful for visualizing and measuring the extent of tumor motion within a low HU
material such as lung tissue. Figure 2.9 is a sagittal image of the MIP mid-tumor.
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Figure 2.9: MIP of the phantom in free breathing state, sagittal plane
2.4.1.2 Average CT
In a similar way to the MIP, the average CT is a 3D image set which consists of
the average HU value over the ten respiratory phases acquired in the 4DCT. Figure
2.10 is a sagittal image of the average CT and is taken in the same plane as Figure 2.9
above for comparison.
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Figure 2.10: Average CT of the phantom in free breathing state, sagittal plane
2.4.2 Breath Hold CT
The breath hold CT was taken by setting the electromechanical cylinder to the
breath hold motion pattern. The couch position was left unchanged from the reference
alignment from the free breathing acquisition. Three CT acquisitions were taken to
assess the repeatability of the breath hold imaging. All three scans were visually
indistinguishable and deemed to have been acquired appropriately for a breath hold
treatment plan. An image of the mid-tumor sagittal plan is shown in Figure 2.11 and
can be compared to Figure 2.9 and Figure 2.10 which include motion during the
acquisition.
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Figure 2.11: Breath hold CT of the phantom, sagittal plane
2.5

Treatment Planning
Due to the phantom design, the treatment planning must be artificially restricted

to avoid clinically unrealistic beam geometries. The phantom lacks a contralateral lung
and requires a tilted stand, which is placed on the treatment couch.

Thus, beam

geometries resulting in irradiation from the contralateral side or the posterior side were
avoided. In general, the beam angles should be limited between anterior and left lateral
fields.
Four treatment plans were generated. One plan was a passive scattered plan
which utilized respiratory gating on Gantry 1 at the PTC-H. The second plan was a
scanning beam plan for delivery on Gantry 3 at the PTC-H which included 2.13 cm of
target motion in amplitude. The third plan was passive scattered plan which did not
utilize respiratory gating on Gantry 1 at the PTC-H which included 1.5 cm amplitude.
The fourth plan was a scanning beam plan for delivery on Gantry 3 at the PTC-H which
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included 1.5 cm of target motion in amplitude. The four plans mentioned above are
representative of both passive scattered treatment techniques and spot scanned treatment
techniques used currently in the radiation oncology field. An appropriately delivered
scattered breath hold treatment effectively yields a static irradiation state. Therefore,
the influence of motion amplitude can be assessed as well as the influence of the
interplay effect between passive scattered treatments and spot scanned treatments.
Each treatment plan was set to a single fraction with a prescribed dose of 600
CcGE.

Clinically, this fractionation scheme is unreasonable, but is convenient to

deliver with a single fraction to the phantom. The prescribed dose of 600 CcGE is a
dose level that yields better statistical results from the TLD and film dosimeters than the
conventional 200 CcGE dose per fraction typical of clinical treatment plans.

To

translate these treatment plans to clinically applicable plans, doses may be multiplied by
ten to result in a 60 CcGE prescription, which is reasonable for proton therapy patients.
2.5.1 Passive Scattered Breath Hold Treatment Plan
A plan was generated for treatment of the target by a passive scattered beam
under breath hold respiratory gating. The prescribed dose was 600 CcGE and included
two beams, an AP and a left lateral beam. Additional beam parameters are listed in
Table 2.3. Proximal, distal and lateral clinical margins were used to achieve adequate
tumor coverage utilizing the conventions currently employed by the PTC-H dosimetry
team. The dose prescription was normalized to 100% of the PTV volume receiving 600
CcGE.
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Passive Scattered Beam Treatment Plan Parameters
Prescription: 600 CcGE
Beam

AP

Lt Lat

Gantry Angle [°]

0

90

Couch Angle [°]

0

0

Energy [MeV]

140

140

SAD [cm]

270

270

SOBP Width [cm]

5

4

Range Modulator Wheel

RMW_13

RMW_13

Range Shifter Thickness [cm]

-

1.3

Dose Rate [MU/min]

100

100

Snout Size [cm]

18 x 18

18 x 18

Field Weight Factor

0.500

0.500

MU

303.3

295.0

Table 2.3: Passive scattered breath hold treatment beam parameters
Screen shots from the passive scattered breath hold treatment plan are shown in
Figure 2.12 and Figure 2.13. Figure 2.12 shows the surface dose at the location of the
heart film. Figure 2.14 shows the DVH of the passive scattered breath hold treatment
plan. The PTV receives an appropriate prescription dose while the ipsilateral lung and
heart receive appropriately low doses.
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Figure 2.12: Resultant heart surface dose from passive scattered treatment plan
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Figure 2.13: Axial isodose plot of the target for the passive scattered breath hold
treatment plan on the left and resultant isodose plot after manual HU adjustment
of the target on the right
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Figure 2.14: DVH of the passive scattered treatment plan showing the PTV,
healthy lung and heart
2.5.1.1 MU Calculation of Scattered Plan
The PCT-H follows a published formalism for MU calculations for passive
scattered treatment plans [52]. To make the calculation process more time efficient,
dose-to-MU measurements in water have been previously performed being modified by
factors which estimate the dose and MU for a patient plan. The patient plan was copied
into the water phantom CT data set. Because the geometry and beam parameters were
copied, the dose at isocenter in the water phantom needs only be modified by the ROF,
SOBPF and RSF to arrive at the dose at isocenter in the phantom plan. The MU is thus
calculated by Equation 9. Where D is the physical dose measured in water by the TPS.
Equation 9
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2.5.1.2 Replanning for Manual Override of Target HU
The target in the passive scattered breath hold plan was manually adjusted such
that the target HU was set to 80 HU. Region of interest measurements showed that the
target had an average HU of approximately -40 HU. Based on the stopping power
measurements which have been done on high impact polystyrene, a material that
behaved similar to the Eclipse calibration curve at the RLSP of high impact polystyrene
should have an HU of 80. The beams, blocks, and compensators were copied into the
new modified CT image set and a 3D dose distribution was calculated with the beam
characteristics left unchanged between plans. Figure 2.13 above shows the replanned
and recalculated dose distribution of the manually adjusted target next to the original
planned dose distribution.
2.5.2 Scanning Beam with 2.13 cm Breathing Amplitude Treatment Plan
The scanned beam plan with 2.13 cm breathing amplitude was generated in
Eclipse TPS using the MIP as a guide to determine the ITV and using the average CT as
the image set to plan on. The pencil beam gantry at PCT-H does not have motion
monitoring equipment, therefore the free breathing imaging was used for the treatment
plan. Similar to the passive scattered plan, the scanned plan utilized the same OAR
criteria as well as the same PTV coverage criteria and prescribed dose. Table 2.4 shows
a number of the plan parameters used in the scanned beam plan. The plan utilized
single field optimization.
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Figure 2.15 shows a screen shot of an axial slice of the scanned beam treatment
plan. Figure 2.16 shows the DVH of the scanned beam treatment plan. The PTV
receives adequate prescription coverage, but contains hot spots resulting in a maximum
dose of approximately 8 CGE. The ipsilateral lung and the heart receive appropriately
low doses.
Scanned Beam Treatment Plan Parameters
Prescription: 600 CcGE
Beam

AP

Lt Lat

Gantry Angle [°]

0

90

Couch Angle [°]

0

0

Energy [MeV]

118.6

108.0

SAD [cm]

270

270

SOBP Width [cm]

4.95

4.10

Energy Absorber

-

-

Dose Rate [MU/min]

100

100

Maximum Field Size [cm]

30 x 30

30 x 30

Field Weight Factor

0.500

0.500

MU

154.62

173.85

Table 2.4: Scanned beam with 2.13 cm breathing amplitude treatment beam
parameters
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Figure 2.15: Axial isodose plot of scanned beam with 2.13 cm breathing amplitude
treatment plan on the left and resultant isodose plot after manual HU adjustment
of the target on the right
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Figure 2.16: DVH of scanned beam treatment plan with PTV, healthy lung, and
heart
2.5.2.1 Dose Verification
The dose delivery was verified by the patient specific techniques used by the
PTC-H for the spot scanned beam. The beam information from the treatment plan was
exported to a cube of water and the dose was recalculated based on both beams entering
with a gantry angle of 0º.

At three depths within the water phantom the two-

dimensional isodose plots were made on the central axis for each beam.

A two-

dimensional ionization chamber array called the MatriXX (IBA, Schwarzenbruck,
Germany) was used with the corresponding depths of water equivalent buildup, to
measure two-dimensional dose for each beam. The two-dimensional measured and
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calculated doses were analyzed by the gamma index with a minimum acceptance of 3%
/ 3 mm 90% pass.
2.5.2.2 Replanning for Manual Override of Target HU
The target in the spot scanned plan was manually adjusted differently than that
of the passive scattered breath hold plan. The region of the target that was the highest
intensity was assigned an HU of 80, while a surrounding region which in the average
image was blurred between target and lung material was set to an HU of -100. The
beams were copied into the new modified CT image set and a 3D dose distribution was
calculated with the beam characteristics left unchanged between plans. Figure 2.15
above shows the replanned and recalculated dose distribution of the manually adjusted
target next to the original planned dose distribution.
2.5.3 Passive Scattered Beam with 1.5 cm Breathing Amplitude Treatment Plan
The scattered beam plan under free breathing motion of 1.5 cm in amplitude was
generated in Eclipse TPS. Target contouring was performed on the MIP and dose
calculations were done on the average CT image set, similarly to the other free
breathing treatment plans. Table 2.5 shows a number of the plan parameters used in the
passive scattered free breathing treatment plan. The contoured plan was generated in
the same way as described in section 2.5.2.2 above.
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Scattered Beam Free Breathing Treatment Plan Parameters
Prescription: 600 CcGE
Beam

AP

Lt Lat

Gantry Angle [°]

0

90

Couch Angle [°]

0

0

Energy [MeV]

160

140

SAD [cm]

270

270

SOBP Width [cm]

5

4

Range Modulator

RM_20

RM_21

Range Shifter Thickness [cm]

2.7

1.5

Dose Rate [MU/min]

100

100

Snout Size [cm]

18 x 18

18 x 18

Field Weight Factor

0.500

0.500

MU

262.9

272.6

Table 2.5: Passive scattered free breathing treatment beam parameters
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Figure 2.17: Axial isodose plot of passive scanned free breathing treatment with
1.5 cm amplitude on the left and resultant isodose plot after manual HU
adjustment of the target on the right

57

PTV
Lung
Heart

Figure 2.18: DVH of the passive scattered free breathing treatment plan with 1.5
cm amplitude motion

2.5.4 Scanning Beam with 1.5 cm Breathing Amplitude Treatment Plan
The scanned beam plan with 1.5 cm breathing amplitude was generated in
Eclipse TPS identically to the previous scanning beam plan. Table 2.6 shows a number
of the plan parameters used in the scanned beam plan. The plan utilized multi-field
optimization.
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Scanned Beam Treatment Plan Parameters
Prescription: 600 CcGE

Table 2.6:

Beam

AP

Lt Lat

Gantry Angle [°]

0

90

Couch Angle [°]

0

0

Energy [MeV]

121.2

109.4

SAD [cm]

270

270

SOBP Width [cm]

5.35

4.62

Energy Absorber

-

-

Dose Rate [MU/min]

100

100

Field Size [cm]

25 x 25

25 x 25

Field Weight Factor

0.500

0.500

MU

128.99

144.45

Scanned beam with 1.5 cm breathing amplitude treatment beam

parameters
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Figure 2.19: Axial isodose plot of scanned beam with 1.5 cm breathing amplitude
treatment plan on the left and resultant isodose plot after manual HU adjustment
of the target on the right
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PTV
Lung
Heart

Figure 2.20: DVH of the spot scanned beam treatment plan with 1.5 cm breathing
amplitude motion
2.5.4.1 Dose Verification
Point dose measurements were made with a PTW TN23343 Markus chamber
(PTW, Freiburg, Germany) in both the AP and left lateral beams at the WET depth and
off axis location of the TLD, which were 7.5 cm and 2 mm respectively. Both beam
parameters were copied into a solid water phantom image set used by the PTC-H for
QA measurements. Typically in QA measurements, both beams would be treated at the
same gantry angle, however, the AP QA measured was done at 0˚ and the left lateral
QA measurement was done at 90˚ to avoid uncertainty from gantry angle dependence.
2.6

Treatment Delivery
All treatments were delivered at the PTC-H and consisted of alignment to gantry

lasers and irradiation of the two fields. Following the full treatment delivery, the insert
was removed from the phantom. The irradiated film and TLD were removed and
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replaced with unused film and TLD. The treatment plan was delivered three times
without moving the phantom shell on the treatment couch.
2.6.1 Passive Scattered Breath Hold Plan
The scattered beam was delivered with the use of the RPM system to deliver a
breath hold treatment. The phantom was aligned with the lasers to the fiducial markers.
The phantom was then shifted to align to the target isocenter. The shift to isocenter
required was 4 mm to the patient left, 3.3 cm down and 9 mm into the gantry. The
RPM reflective box was set within view of the CCD camera. The lead screw motor was
set to repeat the breath hold pattern. Treatment began with the AP beam and was
paused when the insert went out of the breath hold phase of the breathing cycle. Once
the AP beam was delivered, the Lateral field was delivered in the same way.
2.6.2 Spot Scanning Beam with 2.13 cm Breathing Amplitude Plan
The phantom was aligned on the treatment couch with respect to the laser
alignment and the three fiducial markers. Isocenter was determined to be shifted from
the surface fiducials by 4 mm to the patient left, 3 cm down and 1.9 cm into the gantry.
The treatment couch was moved to align the planned isocenter with the gantry
isocenter. The phantom was then imaged with an AP and a lateral x-ray image. The
images were then compared to the DRRs generated in the TPS. Because of the ridged
landmarks such as the ribs, the image guided shift was found to be only necessary in
one direction, a 2 mm shift in the superior direction. Prior to irradiation, the free
breathing motion file was run with an indefinite loop. The patient plan was run in
treatment mode with audio and visual verification that the motion insert remained in
motion during the entirety of the treatment delivery.
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2.6.3 Passive Scattered Free Breathing Plan
The phantom was aligned with the lasers to the fiducial markers. To align
isocenter to the target, the couch was shifted 7 mm to patient left, 2.9 cm down and 2.1
cm into the gantry. Figure 2.21 below shows the treatment setup for this treatment plan.

Figure 2.21: Image of the left lateral beam geometry for the passive scattered free
breathing treatment
2.6.4 Spot Scanned Beam with 1.5 cm Breathing Amplitude Plan
The phantom was aligned on the couch with the lasers to the fiducial markers.
Isocenter shifts were identical to the passive scattered free breathing plan mentioned
above because the target and structure contours are identical.
2.7

Measured vs Planned Dose Analysis
After the film and TLD were measured, the measured dose was compared with the

planned dose by the following method. Film and TLD corrected doses were registered
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using an established MATLAB software, RPCFilm. Each piece of film contains pin
pricks with known spacing to identify the orientation of the film with respect to the
planned CT data set. In this way, the film was registered to the 3D plan with a 3D dose
distribution. Therefore, the film was correctly registered to the reconstructed dose
along the measured plane.
Following registration a 2D gamma analysis was performed on each film plane,
excluding the pin pricks as well as slits used to create the orthogonal film geometry.
Since the phantom has not been studied previously, a baseline pixel passing percentage
had not been established. Two dose profiles were taken across each piece of film and
were plotted with the TPS calculated dose profile along the same lines. Within each
treatment plan, the profiles were averaged and analyzed for repeatability.

3
3.1

Results and Discussion
Bone Equivalent Material Testing
Of the nine materials tested for bone equivalency, the stopping power ratios for

two types of clay were sufficiently close enough to the Eclipse calculated stopping
power vs. HU calibration curve as well as within an appropriate HU range for bony
anatomy. These two clay materials are labeled material 2 and material 3 in Figure 3.1.
The reproducibility of HU and relative stopping power were assessed for these two
materials by making new samples from different batches of the same type of clay.
The results of the second batch along with the results from the first batch are
shown in Figure 3.2 where material 2.1 and 3.1 are the second batch results for material
2 and material 3, respectively. While the original material 2 measurement was identical
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to the Eclipse calibration curve, the second batch was significantly different in both HU
and relative stopping power. The reproducibility of material 3 in relative stopping
power was precise as well as accurate to 0.9% of the calibration curve at the average
HU of the two measurements with σHU of 1.4% and σRLSP of 0.7%.
The bone equivalent material that was chosen conforms well to RPC established
baseline criteria for adequate phantom use in proton therapy, which is to be within ±5%
agreement of the Eclipse calculated stopping power vs. HU calibration curve. As
determined with the bone material testing, a couple of acceptable proton equivalent
phantom materials were found. While the ±5% criteria was met, it was also equally
important that the material be reproducible in case it had to be used for repairs or
additional new phantoms. The average RLSP agreement of material batches 2 and 2.1
to the calibration curve was 1.4%, yet they demonstrate very poor reproducibility as
seen in Figure 3.2 as compared to material batches 3 and 3.1.
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Figure 3.1: HU and relative stopping power of the materials tested for bone
equivalency
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Figure 3.2: HU and relative stopping power reproducibility results of the two best
proton bone substitutes
3.2

Phantom Design and Dimensions
The proton lung phantom was designed with the considerations stated in section

2.1.1. The drawings were used in the fabrication of the phantom. Design components
such as the ribs, dosimetry insert, and heart structure can be visualized in a sagittal
transparent cross section in Figure 3.3. Figure 3.4 is a sagittal transparent cross section
with dimensions in inches. Figure 3.5 and Figure 3.6 show the superior and inferior
ends of the phantom respectively. In these figures, the location of the heart film plane
can be seen as the interface between the heart structure and the lung material.
Additionally, these figures show the anthropomorphic design of the anterior portion of
the phantom which increases in dimension towards the inferior end of the phantom.
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Full technical drawings of the phantom and stands are included in section 5.1 of the
appendix. Images of the phantom after fabrication are shown in Figure 3.7 and Figure
3.8 with insert motion facilitated by an electromechanical cylinder and lead screw,
respectively.

Figure 3.3: Sagittal diagram of the phantom and its materials
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Figure 3.4: Sagittal diagram of the phantom with dimensions
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Figure 3.5: Superior end of phantom with dimensions
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Figure 3.6: Inferior end of phantom with dimensions
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Figure 3.7: Image of the phantom assembly with electromechanical cylinder based
motion

Figure 3.8: Image of phantom assembly with lead screw based motion
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3.2.1 Phantom Design Conformity to Eclipse Calibration Curve
The phantom was designed with the intention that no targets or normal tissue
structures would require manual override of Hounsfield Units to obtain the appropriate
RLSP value. Manual overrides of regions require more time to plan a treatment.
Manual overrides also may be a source of error in the treatment plan and delivery, even
more so in 4DCT acquisitions than in conventional CT acquisitions. Prior to the
construction of the phantom, an estimation of the water equivalent depth of the center of
the tumor during full inhalation and full exhalation from the AP beam line as well as the
left lateral tumor water equivalent depth were calculated to the center of the target. All
range estimations were based only on the proton equivalent materials in the beam path
and the distance traveled within each material. From the known uncertainty in the bone
material stopping power, an estimation of the propagated range uncertainty was
estimated for all cases.
In the AP full inhalation case, the range difference was calculated to be 0.2 mm
overshoot compared to the Eclipse calculation. At full exhalation, the range difference
was calculated to be less than 0.01 mm compared to the Eclipse calculation. In the left
lateral cases, the actual phantom WET was higher than the Eclipse calculated WET by
approximately 0.9 mm and 0.8 mm for the rib-in-path and rib-out-of-path cases
respectively, as shown in Figure 3.11 and Figure 3.12. The range of uncertainty (2σ) of
the actual WET included the Eclipse calculated value in the AP cases as shown in
Figure 3.9 and Figure 3.10. The left lateral beam cases were not inclusive of the
Eclipse calculated value within the range of uncertainty.
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The proton scanning beam at MD Anderson Cancer Center has a range adjustment
step size of 0.1 g/cm2 [16]. This means that a systematic difference in the water of less
than 0.5 mm results in the same spot delivery. However, in a phantom with a high
composition of low density material, such as balsa, the range adjustment step size
would be larger than 1 mm in some cases. In this case, the systematic difference
between the phantom materials and the Eclipse calculation becomes on the order of
rounding error. As discussed in section 1.5.5, the Eclipse calculated range value also
includes the uncertainty in the HU to RLSP calibration curve, which is represented in
the Eclipse calculated error bars. Figure 3.9 - Figure 3.12 have gridline units equal to
the water equivalent range adjustment step size of the scanning beam at the MD
Anderson proton therapy center to illustrate the difference between the actual and
calculated WET in each case. It is also important to note that the range uncertainty
when using EBT film for proton therapy dosimetry is approximately 0.5 mm [50].
Therefore, with all four of the hypothetical beam line cases in submillimeter agreement
to the Eclipse calculated WET, the range difference of using the lung phantom tissue
substitutes is within the range of uncertainty in the film dosimetry and adjustment step
size.
While this analysis indicates that individual pathlengths along sample beam paths
show a low range uncertainty at the center of the target, the target itself perturbs the
beam greater than the TPS calculates. The combination of a material that over responds
and one that under responds for example may yield agreement at one depth, while
differing at other depths.

Maximization of material RLSP agreement to the TPS

minimizes the effect of range uncertainties.
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AP Full Inhalation

Actual
Eclipse Calculated

7.10
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Figure 3.9: AP Full inhalation WET in phantom with propagated uncertainty
compared to Eclipse calculated

AP Full Exhalation

Actual
Eclipse calculated

7.9

8.0

8.1

8.2

8.3

8.4
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Figure 3.10: AP Full exhalation WET in phantom with propagated uncertainty
compared to Eclipse calculated
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Left Lateral with ribs in path
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Figure 3.11:

Left lateral WET in phantom through ribs with propagated

uncertainty compared to Eclipse calculated

Left Lateral with ribs out of path

Actual
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5.50

5.60
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Figure 3.12:

Left lateral WET in phantom in between ribs with propagated

uncertainty compared to Eclipse calculated
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3.3

Motion Profile
Tumor motion was simulated using a sin6(x) type function. Others have shown

that such a function is accurate to simulate respiratory motion [30]. Figure 3.13 is an
example of sin6(x) type breathing motion with an amplitude of 2.13 cm and period of 6
seconds.

Sin6 breathing pattern
Cylinder relative position (mm)
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Figure 3.13: Example of a sin6 type breathing pattern with 6 second period
The sin6(x) type breathing motion profile used to generate Figure 3.13 was used
to

generate

the

electromechanical

cylinder

motion

instruction

file.

The

electromechanical cylinder motion trace pattern is shown in Figure 3.14. The motion
pattern did not exactly reproduce the sin6(x) type breathing profile; however, the motion
was highly reproducible as well as similar to a clinically relevant breathing pattern.
Sixteen points were taken along the sin6(x) function and assigned a position and a
velocity. The ordinate of the plot in the position trace is in units of pulses, which is the
smallest unit of motion the electromechanical cylinder can produce.

For this
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electromechanical cylinder, a pulse is equal to 0.0075 mm. The peak of the position
trace corresponds to position at maximum inspiration, which is 2.13 cm inferior to
position of maximum exhalation. Once the electromechanical cylinder was replaced by
the lead screw motor, the motion profile was converted to the lead screw motor
software VMX (Velmex, Inc., Bloomfield, NY). The same displacement and velocity
points were used to generate the free breathing file for the new motion system as can be
seen in Figure 3.15.

Figure 3.14 Example of a free-breathing electromechanical cylinder position trace
with a 6 second period
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Figure 3.15: Motion profile generated for VMX motion platform identical to that
of electromechanical cylinder
From the sin6(x) type motion, a breath hold simulation was generated by simply
increasing the delay between breath cycles. Breath hold treatments are common in
radiation oncology; however, in lung cancer cases the breath hold time is typically
shorter than patients without cancer. Figure 3.16 shows an example of a modified
sin6(x) type function to simulate a breath hold treatment where the breath hold time is
approximately 13 seconds.
Figure 3.17 shows the electromechanical cylinder motion trace that was
generated from the free breathing file, but incorporated a longer time at maximum
inspiration. The breath hold time is approximately 13 seconds. The breath hold pattern
can be set to repeat indefinitely, which is not clinically observed, but does allow for a
simple implementation of breath hold simulation. In addition to the previous two
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motion types, patient acquired data from a 4DCT study could also be used to simulate
an irregular breathing pattern.

Figure 3.16: Example of a sin6 type breath hold pattern with a 19 second period

Figure 3.17 Example of a position trace of a breath hold pattern with a period of
approximately 19 seconds
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3.4

Passive Scattered Breath Hold Treatment Dosimetry Measurements

3.4.1 MU Requirements
The resultant MU required for the AP and Lateral beams in the passive scattered
plan were calculated to be 303 MU and 295 MU, respectively.
3.4.2 Point Dose Comparison
The point dose in each trial was compared to the dose at the same point
calculated by the TPS.

The measurements and calculations were analyzed by

calculating the CV and the ratio of the measured to the calculated point doses.
Individual trial TLD results are shown in Table 3.1. Each trial contained two
double-loaded TLD measurements that were averaged.

The CV for the TLD

measurements between trials of the passive scattered breath hold treatment delivery was
calculated to be 1.5% with an average RPC/institution ratio of 1.027 for the contoured
planned TLD dose and 1.002 for the original planned TLD dose. The CV of all of the
TLD readings for all trials was 2.2%. Measured TLD doses were higher than planned
doses for all three trials.
Average Measured Average Calculated RPC/Institution
TLD Dose [CcGE]

Dose [CcGE]

Trial 1

630.9

603.6

1.045

Trial 2

615.2

603.6

1.019

Trial 3

613.4

603.6

1.016

Table 3.1: Passive scattered breath hold plan point dose comparison by trial using
the contoured planned TLD dose
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3.4.3 Planar Dose Distribution Comparison
The passive scattered breath hold dose distribution measurements were analyzed
against the original calculated treatment plan as well as against the treatment plan with a
target that was contoured and its HU manually adjusted. Table 3.2 shows the percent of
pixels passing the ±5% / 5mm criteria of the original plan, while Table 3.3 shows the
percent of pixels passing the same criteria when the target HU was adjusted. The
average improvement of the contoured plan was an 11.8% increase in the percentage of
the pixels passing the criteria. The greatest improvement was found in the axial planes
which had a percentage point passing difference of 13.8%, 21.6% and 24.0% for trials
1, 2 and 3, respectively. Figure 3.18 is a boxplot comparison of the two plans. The
median of the contoured plan was calculated to be 10.1% increase in the percentage of
the pixels passing than the original plan.
Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

79.5%

Coronal

74.4%

Axial

81.6%

Sagittal

76.7%

Coronal

70.0%

Axial

66.8%

Sagittal

75.30%

Coronal

73.7%

Axial

64.9%
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Table 3.2: Gamma index (±5%/5mm criteria) for each plane and trial for the
passive scattered breath hold plan
Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

80.4%

Coronal

82.3%

Axial

95.4%

Sagittal

81.3%

Coronal

82.9%

Axial

88.5%

Sagittal

84.5%

Coronal

84.8%

Axial

89.0%

Table 3.3: Gamma index (±5%/5mm criteria) for each plane and trial for the
passive scattered breath hold contoured plan when the target HU was adjusted
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Figure 3.18: Comparison of passing percentage distributions for the film planes in
the passive scattered breath hold plan and the contoured plan when the target HU
was adjusted
3.4.4 Distance to Agreement
The target RLSP difference from the TPS resulted in a notable discrepancy
between the measured film dose profiles from the original planned dose profiles distal
to the target. After manual HU adjustment of the target, the measured and planned
profiles resulted in a smaller distance to agreement in the region distal to the target.
This effect is shown in Figure 3.19. All three profiles agree well proximal to the target,
entering from the positive distances labeled as patient left. The divergence between the
original plan and the two measured dose profiles, is due to the material RLSP properties
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of the target material being different from the RLSP properties the TPS calculates.
Axial films resulted in the highest improvement in gamma index pass percentages
because the axial plane has both beams displaying the distal disagreement with the
original planned dose. Improvements due to contouring and adjusting the target HU
only occur within the target region or distal to the target. The lateral dose profiles
across the target comparing the calculations and measurements exhibit similar
penumbra discrepancies to the original plan, which can be seen in Figure 3.20 where the
lateral penumbra of the two treatment plans are nearly identical. The complete set of
TPS calculated and measured dose profiles for the passive scattered breath hold
treatment can be found in section 5.3.1 with distance to agreement measurements at the
5 CcGE and 3 CcGE dose levels where applicable and greater than 1 mm.

Figure 3.19: Comparison of measured film, original plan, and contoured plan
when the target HU was adjusted dose profile from right to left on axial film
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Figure 3.20: Comparison of measured film, original plan, and contoured plan
when the target HU was adjusted dose profiles from right to left on sagittal film
3.5

Scanned Beam with 2.13 cm Breathing Amplitude Dosimetry Measurements

3.5.1 Dose Verification
The clinical dose verification quality assurance as described in section 2.5.2.1
met the acceptable ±3% / 3 mm pass criteria for all depths within each beam. Table 3.4
shows the ±3% / 3 mm percent passing points for each depth and beam. Ideally, plans
should yield at least 90% passing points at ±2% / 2 mm, however, only beams that yield
less than 90% passing points at ±3% / 3 mm are considered for either replanning or a
modification of the treatment plan.
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Verification Plan Results
Field

Depth (cm)

Pass (%)

AP

6.9

95.7

7.4

90.2

8.4

97.2

5.9

89.8

6.9

98.8

Left Lat.

Table 3.4: Verification plan results for the 2.13 cm breathing amplitude spot
scanned treatment plan
3.5.2 Point Dose Comparison
The point dose comparison was made by comparing the measured TLD readings
with the average calculated dose over the movement range of the TLD. The average
calculated dose of the TLD was determined to be 692.4 CcGE for the original plan and
714.0 CcGE for the contoured plan. The measured averages for all three irradiations
was 681.0 CcGE corresponding to a RPC to institution ratios of 0.954 and 0.984 for the
contoured (target HU adjusted) and original plans, respectively.

The three trials

resulted in a CV of 2.9%. Individual TLD trial results for the contoured plan are shown
in Table 3.5. The CV of all of the TLD readings for all trials was 4.3%. This variance
corresponds approximately to twice that of the passive scattered breath hold TLD.
Measured TLD doses were lower than planned doses for all three trials.
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Average Measured Average Calculated RPC/Institution
TLD Dose [CcGE]

Dose [CcGE]

Trial 1

676.1

714.0

0.947

Trial 2

697.4

714.0

0.938

Trial 3

669.5

714.0

0.977

Table 3.5: Spot Scanned beam with 2.13 cm breathing amplitude contoured plan
(target HU adjusted) point dose comparison by trial
3.5.3 Planar Dose Distribution Comparison
The average pixel passing percentages for the original plan was 65.6%. For the
contoured plan the average was 75.2%. The contoured plan resulted in an average pixel
passing percentage point difference of 9.6%. Similarly to the passive scattered breath
hold plan, the film plane of greatest improvement from contouring the target was the
axial plan with percentage point differences of 14.4% and 13.3% for trials 1 and 3,
respectively. Table 3.6 shows the pass percentages of the planes in each trial for the
original plan, while Table 3.7 shows the pass percentages of the planes in each trial for
the contoured plan (target HU adjusted). The axial film in trial 2 was omitted from
analysis because it was not within the insert during irradiation. Figure 3.21 shows a
boxplot distribution of both the original and contoured plan (target HU adjusted)
gamma indices.

While the contoured plan (target HU adjusted) yielded a tighter

distribution of passing percentages, it did include an extreme outlier, which is shown as
a red plus mark and is greater than -3σ from the median.
Average pixel passing percentages in the 60% range are quite low in the
experience of the RPC. Reasons for low pixel passing percentages for the original plan
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include target material RLSP discrepancy, the interplay effect, high dose gradients, as
well as severe target motion amplitude for this treatment modality. Upon adjusting the
target HU, the regions of highest failure were in the secondary adjusted target region.
Because the amplitude was the largest out of all of the plans delivered, the assumption
of a single HU for the secondary target region included the widest uncertainty. To
visualize this disagreement, the reader is referred to Figure 3.22 where the red failure
regions in the contoured plan correspond in both the sagittal and coronal planes to this
blurred target region.
Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

77.2%

Coronal

58.0%

Axial

66.5%

Sagittal

64.9%

Coronal

46.9%

Axial

-

Sagittal

73.8%

Coronal

74.6%

Axial

62.9%

Table 3.6: Gamma index (±5%/5mm) for each plane and trial for the spot scanned
plan
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Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

79.6%

Coronal

72.0%

Axial

80.9%

Sagittal

77.1%

Coronal

57.6%

Axial

-

Sagittal

76.8%

Coronal

81.3%

Axial

76.2%

Table 3.7: Gamma index (±5%/5mm) for each plane and trial for the spot scanned
contoured plan (target HU adjusted).
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Figure 3.21: Comparison of passing percentage distributions for the film planes in
the spot scanned plan with 2.13 cm breathing amplitude and the contoured plan

91

Figure 3.22: Trial 2 of spot scanned plan with 2.13 cm breathing amplitude when
the target HU was adjusted adjustment gamma analyses

3.5.4 Distance to Agreement
The measured dose profiles for the spot scanned treatment with 2.13 cm
breathing amplitude differed more between each other than for any of the other
treatment types. As an example, the top plot in Figure 3.23 demonstrates that the
average film dose profile agrees with the planned dose profile everywhere within the 5
mm distance to agreement criteria. However, the lower plot in Figure 3.23 shows that
the doses vary noticeably especially in the region 2 cm superior to the film center. Film
dose used in profile plots as well as gamma analysis was normalized by the TLD dose,
and in the case of the spot scanned treatment with 2.13 cm amplitude, the TLD dose had
the largest CV out of all of the treatment types. Additionally, the film and TLD are
influenced by the largest amplitude of motion studied and thus have a higher
susceptibility of dose differences from the interplay effect. The complete set of profiles
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for the passive scattered breath hold treatment can be found in section 5.3.2 with
distance to agreement measurements at the 5 CcGE and 3 CcGE dose levels where
applicable and above 1 mm.

Figure 3.23:

Coronal film profile average (above) and individual (below)

compared to contoured (target HU adjusted) TPS calculations.
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3.6

Passive Scattered Free Breathing Treatment Dosimetry Measurements

3.6.1 MU Requirements
The resultant MU required for the AP and Lateral beams in the passive scattered
free breathing plan were calculated to be 263 MU and 273 MU, respectively.
3.6.2 Point Dose Verification
Individual trial TLD results are shown in Table 3.8. Each trial contained two
double-loaded TLD measurements averaged.

The CV for the TLD measurements

between trials of the passive scattered breath hold treatment delivery was calculated to
be 0.4% with an average RPC/institution ratio of 0.969 for the contoured planned TLD
dose and 0.971 for the original planned TLD dose. The CV of all of the TLD readings
for all trials was 0.74%. Measured TLD doses were lower than planned doses for all
three trials.
Average Measured Average Calculated RPC/Institution
TLD Dose [CcGE]

Dose [CcGE]

Trial 1

607.3

628.4

0.966

Trial 2

609.7

628.4

0.971

Trial 3

610.4

628.4

0.970

Table 3.8: Passive scattered free breathing contoured (target HU adjusted) plan
point dose comparison by trial
3.6.3 Planar Dose Distribution Comparison
The average pixel passing percentage for the original plan was 62.5%. The
average pixel passing percentage for the contoured plan (target HU adjusted) was
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73.9%.

The percentage point difference between the contoured and the original

averages was 11.4%.
Similarly to the spot scanned plan with 2.13 cm amplitude, the passive scattered
free breathing treatment yielded pixel pass percentages in the 60% range for the original
plan and in the 70% range for the contoured plan (target HU adjusted). Average pixel
passing percentages for the breath hold and free breathing passive scattered contoured
plans were 85.4% and 73.9%, respectively. This difference demonstrates the effect of
motion as well as the manual HU adjustment of the secondary target region.
Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

64.0%

Coronal

67.7%

Axial

57.2%

Sagittal

58.6%

Coronal

66.8%

Axial

63.5%

Sagittal

56.8%

Coronal

65.8%

Axial

62.1%

Table 3.9: Gamma index (±5%/5mm) for each plane and trial for the passive
scattered free breathing plan
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Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

75.5%

Coronal

79.6%

Axial

69.7%

Sagittal

70.0%

Coronal

78.9%

Axial

74.3%

Sagittal

68.7%

Coronal

76.8%

Axial

71.4%

Table 3.10: Gamma index (±5%/5mm) for each plane and trial for the passive
scattered free breathing contoured plan
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Figure 3.24: Comparison of passing percentage distributions for the film planes in
the passive scattered free breathing plan and the contoured plan
3.6.4 Distance to Agreement
Of the dose profiles compared, distance to agreement measurements were
generally below the 5 mm criteria parallel to the beam path after manual HU
adjustment. The greatest distance to agreements were found in profiles perpendicular to
the beam path in the region of the lateral penumbra. An example of this can be seen in
Figure 3.25 where the film dose was lower than the planned dose in the penumbra
region.
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Figure 3.25: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered free breathing treatment when the
target HU was adjusted
3.7

Scanned Beam with 1.5 cm Breathing Amplitude Treatment Dosimetry
Measurements

3.7.1 Dose Verification
The TPS calculated doses at the measurement point for the AP field and the left
lateral field were 335.8 CcGE and 297.0 CcGE, respectively. AP and left lateral
measured doses were 337.5 CcGE and 291.2 CcGE, respectively. The AP and left
lateral point dose verification measurements were 0.8% high and 1.7% low,
respectively. This agreement was within the maintained ±2% output consistency for
the proton delivery system. Although the dose was verified within acceptable criteria,
the TLD location was in a region of high dose gradient, over which a 2 mm shift to the
left resulted in a 4% increase in the point dose. Additionally, while the dose was
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verified within a static water phantom, the high dose gradient along with the interplay
effect may yield a wider range of TLD doses within the anthropomorphic phantom.
3.7.2 Point Dose Verification
Individual trial TLD results are shown in Table 3.11. Each trial contained two
double-loaded TLD measurements averaged.

The CV for the TLD measurements

between trials of the spot scanned treatment with 1.5 cm amplitude was calculated to be
1.4% with an average RPC/institution ratio of 0.935 for the contoured planned TLD
dose and 0.913 for the original planned TLD dose. The CV of all of the TLD readings
for all trials was 3.4%. Measured TLD doses were lower than planned doses for all
three trials.
Of all the treatment types, the spot scanned with 1.5 cm amplitude yielded the
greatest measured TLD disagreement with both original TLD dose and contoured TLD
dose. Verification within a homogeneous medium showed that the TLD was located in
a region of high dose gradient which can be visualized in dose profile plots through the
TLD location. All profiles of the contoured and original plans show a dip in measured
film dose particularly on the left, inferior region of the target. The dose profiles can be
found in section 5.3.4. Future irradiations of the phantom should be planned in such a
way as to place lower dose gradients within the TLD if possible.
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Average Measured Average Calculated RPC/Institution
TLD Dose [CcGE]

Dose [CcGE]

Trial 1

567.0

603.0

0.940

Trial 2

566.6

603.0

0.924

Trial 3

557.4

603.0

0.940

Table 3.11: Spot scanned contoured plan with 1.5 cm breathing amplitude point
dose comparison
3.7.3 Planar Dose Distribution Comparison
The average pixel passing percentage for the original plan was 60.1%. The
average pixel passing percentage for the contoured (target HU adjusted) plan was
72.2%.

The percentage point difference between the contoured and the original

averages was 12.1%.
Trial

Trial 1

Trial 2

Trial 3

Film Plane

Percent Passing

Sagittal

54.8%

Coronal

65.3%

Axial

59.8%

Sagittal

61.1%

Coronal

56.4%

Axial

66.9%

Sagittal

54.0%

Coronal

62.6%

Axial

60.2%
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Table 3.12:

Gamma index (±5%/5mm) for each plane and trial for the spot

scanned plan with 1.5 cm breathing amplitude

Trial

Trial 1

Trial 2

Trial 3

Table 3.13:

Film Plane

Percent Passing

Sagittal

66.1%

Coronal

77.4%

Axial

74.8%

Sagittal

72.1%

Coronal

69.1%

Axial

79.7%

Sagittal

65.3%

Coronal

76.7%

Axial

68.6%

Gamma index (±5%/5mm) for each plane and trial for the spot

scanned contoured (target HU adjusted) plan with 1.5 cm breathing amplitude
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Figure 3.26: Comparison of passing percentage distributions for the film planes in
the spot scanned with 1.5 cm breathing amplitude plan and the contoured (target
HU adjusted) plan
3.7.4 Distance to Agreement
Due to the low doses as measured by the TLD in the area of the steep dose
gradient, the distance to agreement between the measured and calculated dose profiles
in the film planes increased. An example of this can be seen in Figure 3.27. The
measured TLD dose was used to normalize the film dose distributions, and in this case,
resulted in profiles that, other than a systematic shift, seem to fit the shape of the
planned contoured dose profile well, but are shifted lower.
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Figure 3.27:

Axial dose profiles comparing the planned TPS dose with the

measured film dose for the scanned treatment with 1.5 cm breathing amplitude
when the target HU was adjusted
3.8

Heart Dosimetry
The film plane located at the surface of the heart structure was used for qualitative

assessment of proper irradiation geometry. Figure 3.28 shows the qualitative planned
dose distribution as well as the qualitative film dose distribution for visual inspection.
Due to the lack of TLD at the location of the film, the absolute dose of the film was not
normalized, however visual inspection of the planned and measured dose distributions
can be used to assess inappropriate irradiation geometries.

The maximum dose

measured on the heart film for all treatment types was approximately 200 CcGE on the
scanned beam with 2.13 cm breathing amplitude. This dose level corresponds to a
region on the film calibration curve which incorporates the greatest measured deviation
from the calibration curve. Additionally, the peak dose on the heart film corresponds to
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a small region of the film. Much of the film was exposed to doses well below the
minimum film calibration measurement, thus they were extrapolated. The film and
planned dose in Figure 3.28 both show a region of lower dose in the shape of the target
and a region of higher dose surrounding the target, which is due to the target margins.
An example of using this film plane to assess inappropriate irradiation could be the
visualization of hot or cold spots not visualized on the treatment plan. Future work for
the phantom may include a point dosimeter within the heart structure directly adjacent
to the film plane to normalize the heart film dose distribution.

Figure 3.28: Planned dose distribution along the plane of the heart film (left) and
measured dose distribution of the heart film (right) with CT overlays for the spot
scanned treatment plan with 2.13 cm breathing amplitude
3.9

Determination of Appropriate Gamma Analysis Criteria
In implementing a QA phantom for the RPC, consideration is needed to determine

the appropriate institution passing criteria. Currently, the RPC photon lung phantom
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uses a ±5% / 5 mm gamma index which is centered around a TLD measured to planned
dose ratio of 0.97. Such a criteria allows for the ±5% dose ratios to be 1.02 and 0.92.
Figure 3.29 shows for the contoured (target HU adjusted) proton plans, the TLD dose
ratios for the phantom studied did not follow the same trend as observed with photons.
Figure 3.29 shows the effects of changing the target material properties where SS2cm,
PSBH, SS1.5cm and PSFB are the spot scanned 2.13 cm amplitude, passive scattered
breath hold, spot scanned 1.5 cm amplitude and passive scattered free breathing
treatments, respectively, and the abbreviations followed by a “C” are the contoured
treatments. When the target HU was manually adjusted, the recalculated TLD to
calculated dose ratios rose for the passive scattered breath hold and spot scanned
treatment with 1.5 cm amplitude, lowered for the spot scanned treatment with 2.13 cm
amplitude and remained constant for the passive scattered free breathing treatment.
Because of the point dose changes that occur from changing the target properties, a
target material that better agrees with the TPS calibration curve is recommended. An
accurately planned TLD dose will better normalize the film dose distributions to result
in more accurate representation of the difference between the planned and delivered
dose to the phantom. Future irradiations may result in a better statistical understanding
of appropriate passing TLD dose ratio criteria.
Each treatment plan irradiated demonstrated an improvement in percentage of
pixels passing the 5% / 5 mm criteria when the target was contoured. Figure 3.30
shows the effects of contoured plans pixel pass percentage over all film planes
irradiated. This finding, demonstrates the necessity of careful material choice when
designing a phantom for use in proton therapy. The distributions of percentage of
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pixels passing the ±5% / 5 mm gamma criteria for each treatment plan type are shown
in Figure 3.31. The of the contoured plans (target HU adjusted), the breath hold
treatment demonstrated the highest pass percentage distribution, the 1.5 cm breathing
amplitude treatments demonstrated similar pass percentage distributions and the 2.13
cm breathing amplitude treatment included an extreme outlier.

Figure 3.29: Measured to planned dose ratios for all original and contoured plans
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Figure 3.30: Comparison of passing percentage distributions for the film planes in
all original plans and contoured (target HU adjusted) plans
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Figure 3.31: Comparison of pixel passing percentages of individual original and
contoured (target HU adjusted) plans

4

Conclusions
The hypothesis that a dynamic heterogeneous anthropomorphic thorax phantom

can be designed and built to evaluate the end-to-end proton therapy treatment
procedures for lung cancer to assure agreement between the measured and calculated
dose within ±5% / 5 mm with a reproducibility of ±2% was met. The phantom was
used in four end-to-end treatments, each of which demonstrated the ability to compare
measured doses to planned doses.
The phantom was successfully able to be utilized as an end-to-end QA tool
simulating proton therapy of a lung tumor. While the average CV of each individual
treatment plan was calculated to be 1.5%, meeting the hypothesized requirement, the
CV of TLD readings before averaging resulted in as much as 4.3% and 3.4% for the
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spot scanned treatment with 2.13 cm amplitude and the spot scanned treatment with 1.5
cm amplitude.

This indicates that the interplay effect may require institutions to

carefully design treatment plans when attempting to accurately irradiate moving point
dosimeters with spot scanned proton beams.
The high impact polystyrene target clearly demonstrated itself insufficient as a
target material within this phantom without manual adjustment of HU. Unfortunately,
manual HU adjustment introduces its own uncertainty, much of which is not easily
quantified. In the case of static irradiation, manual HU adjustment is has the potential
to be an accurate method for yielding planned and measured agreement, assuming the
target is contoured very well and the material HU and RLSP have been measured very
accurately. However, when the target is in motion, manual HU adjustment requires the
acceptance of greater uncertainty by either adjusting the calibration curve, which affects
all pixels within the adjusted range, or adjusting the HU of regions that contain both
target material and balsa wood on the average image. Thus, in order to use the phantom
for its intended purpose, the target should be replaced with either solid water or blue
water.
The current lung phantom pass criteria used by the RPC was not met for any of the
treatment types involving free breathing motion. This indicates that either the RPC
reduce pass criteria for this phantom, or ask institutions to attempt motion mitigation
techniques such as breath hold, or other gating methods.
The addition of accurate bone simulating material successfully demonstrated that
an added heterogeneity can be properly treated by the PTC-H beam lines. In the static
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irradiation case of the breath hold treatment, the addition of rib simulants did not
noticeably affect the ability to deliver the planned dose to the phantom. No bands of
inappropriate rib simulant perturbation were noticeable in any of the film planes. The
incorporation of the rib simulants will effectively assess a proton center’s ability to
accurately treat through bony anatomy and may prove useful for the implementation of
future range or TPS algorithm studies as an end-to-end QA tool.

5
5.1

Appendix
Phantom and Support Technical Drawings
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Figure 5.1: Technical drawing of phantom assembly
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Figure 5.2: Technical drawing of phantom
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Figure 5.3: Technical drawing of phantom stand
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Figure 5.4 Technical drawing of electromechanical cylinder stand
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Figure 5.5: Technical drawing of the heart insert
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5.2

Gamma Analysis

5.2.1 Passive Scattered Breath Hold Plan

(a) Sagittal 79.5% pass

(b) Axial 81.6% pass

(c) Coronal 74.4% pass
Figure 5.6: Trial 1 of passive scattered breath hold plan gamma analyses
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(a) Sagittal 76.7% pass

(b) Axial 66.8% pass

(c) Coronal 70.0% pass
Figure 5.7: Trial 2 of passive scattered breath hold plan gamma analyses
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(a) Sagittal 75.0% pass

(b) Axial 64.9% pass

(c) Coronal 73.7% pass
Figure 5.8: Trial 3 of passive scattered breath hold plan gamma analyses
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(a) Sagittal 80.4% pass

(b) Axial 95.4% pass

(c) Coronal 82.3% pass
Figure 5.9: Trial 1 of passive scattered breath hold plan when the target HU was
adjusted gamma analyses
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(a) Sagittal 81.3% pass

(b) Axial 88.5% pass

(c) Coronal 82.9% pass
Figure 5.10: Trial 2 of passive scattered breath hold plan when the target HU was
adjusted gamma analyses
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(a) Sagittal 84.5% pass

(b) Axial 89.0% pass

(c) Coronal 84.8% pass
Figure 5.11: Trial 3 of passive scattered breath hold plan when the target HU was
adjusted gamma analyses
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5.2.2 Spot Scanned Plan with 2.13 cm Breathing Amplitude

(a) Sagittal 77.2% pass

(b) Axial 66.5% pass

(c) Coronal 58.0% pass
Figure 5.12: Trial 1 of spot scanned plan with 2.13 cm breathing amplitude gamma
analyses
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(a) Sagittal 64.9% pass

(b) Coronal 46.9% pass

Figure 5.13: Trial 2 of spot scanned plan with 2.13 cm breathing amplitude
gamma analyses
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(a) Sagittal 73.8% pass

(b) Axial 62.9% pass

(c) Coronal 74.6% pass
Figure 5.14: Trial 3 of spot scanned plan with 2.13 cm breathing amplitude gamma
analyses
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(a) Sagittal 79.6% pass

(b) Axial 80.9% pass

(c) Coronal 72.0% pass
Figure 5.15: Trial 1 of spot scanned plan with 2.13 cm breathing amplitude when
the target HU was adjusted gamma analyses
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(a) Sagittal 77.1% pass

(b) Coronal 57.6% pass

Figure 5.16: Trial 2 of spot scanned plan with 2.13 cm breathing amplitude when
the target HU was adjusted adjustment gamma analyses
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(a) Sagittal 76.8% pass

(b) Axial 76.2% pass

(c) Coronal 81.3% pass
Figure 5.17: Trial 3 of spot scanned plan with 2.13 cm breathing amplitude when
the target HU was adjusted gamma analyses

127

5.2.3 Passive Scattered Free Breathing Plan

(a) Sagittal 64.0% pass

(b) Axial 57.2% pass

(c) Coronal 67.7% pass
Figure 5.18: Trial 1 of passive scattered free breathing plan gamma analyses
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(a) Sagittal 58.6% pass

(b) Axial 63.5% pass

(c) Coronal 66.8% pass
Figure 5.19: Trial 2 of passive scattered free breathing plan gamma analyses
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(a) Sagittal 56.8% pass

(b) Axial 62.1% pass

(c) Coronal 65.8% pass
Figure 5.20: Trial 3 of passive scattered free breathing plan gamma analyses
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(a) Sagittal 75.5% pass

(b) Axial 69.7% pass

(c) Coronal 79.6% pass
Figure 5.21: Trial 1 of passive scattered free breathing plan when the target HU
was adjusted gamma analyses
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(a) Sagittal 70.0% pass

(b) Axial 74.3% pass

(c) Coronal 78.9% pass
Figure 5.22: Trial 2 of passive scattered free breathing plan when the target HU
was adjusted gamma analyses
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(a) Sagittal 68.7% pass

(b) Axial 71.4% pass

(c) Coronal 76.8% pass
Figure 5.23: Trial 3 of passive scattered free breathing plan when the target HU
was adjusted gamma analyses
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5.2.4 Spot Scanned Plan with 1.5 cm Breathing Amplitude

(a) Sagittal 54.8% pass

(b) Axial 59.9% pass

(c) Coronal 65.3% pass
Figure 5.24: Trial 1 of spot scanning treatment plan with 1.5 cm breathing
amplitude gamma analyses
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(a) Sagittal 61.1% pass

(b) Axial 66.9% pass

(c) Coronal 56.4% pass
Figure 5.25: Trial 2 of spot scanning treatment plan with 1.5 cm breathing
amplitude gamma analyses
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(a) Sagittal 54.0% pass

(b) Axial 60.2% pass

(c) Coronal 62.6% pass
Figure 5.26: Trial 3 of spot scanning treatment plan with 1.5 cm breathing
amplitude gamma analyses
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(a) Sagittal 66.1% pass

(b) Axial 74.8% pass

(c) Coronal 77.4% pass
Figure 5.27: Trial 1 of spot scanned plan with 1.5 cm breathing amplitude when
the target HU was adjusted gamma analyses
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(a) Sagittal 72.1% pass

(b) Axial 79.7% pass

(c) Coronal 69.1% pass
Figure 5.28: Trial 2 of spot scanned plan with 1.5 cm breathing amplitude when
the target HU was adjusted gamma analyses
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(a) Sagittal 65.3% pass

(b) Axial 68.6% pass

(c) Coronal 76.7% pass
Figure 5.29: Trial 3 of spot scanned plan with 1.5 cm breathing amplitude when
the target HU was adjusted gamma analyses

139

5.3

Film Profiles

5.3.1 Passive Scattered Breath Hold Plan

Figure 5.30: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment
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Figure 5.31: Axial dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment
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Figure 5.32: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment
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Figure 5.33: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment when the
target HU was adjusted
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Figure 5.34: Axial dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment when the
target HU was adjusted
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Figure 5.35: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered breath hold treatment when the
target HU was adjusted
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5.3.2 Scanned with 2.13 cm Breathing Amplitude Plan

Figure 5.36: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 2.13 cm breathing amplitude
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Figure 5.37: Axial dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 2.13 cm breathing amplitude
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Figure 5.38: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 2.13 cm breathing amplitude
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Figure 5.39: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for spot scanned treatment with 2.13 cm breathing amplitude
when the target HU was adjusted
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Figure 5.40:

Axial dose profiles comparing the planned TPS dose with the

measured film dose for spot scanned treatment with 2.13 cm breathing amplitude
when the target HU was adjusted
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Figure 5.41: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for spot scanned treatment with 2.13 cm breathing amplitude
when the target HU was adjusted
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5.3.3 Passive Scattered Free Breathing Plan

Figure 5.42: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered free breathing treatment
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Figure 5.43:

Axial dose profiles comparing the planned TPS dose with the

measured film dose for the passive scattered free breathing treatment
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Figure 5.44: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered free breathing treatment
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Figure 5.45: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered free breathing treatment when the
target HU was adjusted
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Figure 5.46:

Axial dose profiles comparing the planned TPS dose with the

measured film dose for the passive scattered free breathing treatment when the
target HU was adjusted
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Figure 5.47: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the passive scattered free breathing treatment when the
target HU was adjusted
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5.3.4 Scanned with 1.5 cm Breathing Amplitude Plan

Figure 5.48: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 1.5 cm breathing amplitude
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Figure 5.49: Axial dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 1.5 cm breathing amplitude
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Figure 5.50: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 1.5 cm breathing amplitude
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Figure 5.51: Sagittal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 1.5 cm breathing amplitude
when the target HU was adjusted
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Figure 5.52:

Axial dose profiles comparing the planned TPS dose with the

measured film dose for the scanned treatment with 1.5 cm breathing amplitude
when the target HU was adjusted
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Figure 5.53: Coronal dose profiles comparing the planned TPS dose with the
measured film dose for the scanned treatment with 1.5 cm breathing amplitude
when the target HU was adjusted
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